id	sid	tid	token	lemma	pos
work_newopgrnrzfqbeyqnf4pqkzeka	1	1	EP-1199	ep-1199	IN
work_newopgrnrzfqbeyqnf4pqkzeka	1	2	:	:	:
work_newopgrnrzfqbeyqnf4pqkzeka	1	3	The	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	1	4	identification	identification	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	5	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	1	6	putative	putative	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	1	7	biomarkers	biomarker	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	1	8	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	1	9	radioresistance	radioresistance	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	10	in	in	IN
work_newopgrnrzfqbeyqnf4pqkzeka	1	11	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	1	12	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	13	tissue	tissue	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	14	using	use	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	1	15	antibody	antibody	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	16	microarray	microarray	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	17	S650	S650	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	18	3rd	3rd	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	19	ESTRO	ESTRO	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	20	Forum	Forum	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	21	2015	2015	CD
work_newopgrnrzfqbeyqnf4pqkzeka	1	22	EP-1199	EP-1199	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	1	23	The	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	1	24	identification	identification	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	25	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	1	26	putative	putative	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	1	27	biomarkers	biomarker	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	1	28	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	1	29	radioresistance	radioresistance	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	30	in	in	IN
work_newopgrnrzfqbeyqnf4pqkzeka	1	31	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	1	32	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	33	tissue	tissue	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	34	using	use	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	1	35	antibody	antibody	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	36	microarray	microarray	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	37	B.	B.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	38	Onal1	onal1	NN
work_newopgrnrzfqbeyqnf4pqkzeka	1	39	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	1	40	L.	L.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	41	Bowden1	Bowden1	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	42	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	1	43	S.	S.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	44	Seedat1	Seedat1	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	45	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	1	46	S.	S.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	47	Maher2	Maher2	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	1	48	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	1	49	I.A.	I.A.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	1	Hunter3	Hunter3	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	2	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	3	L.	L.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	4	Cawkwell1	Cawkwell1	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	5	1University	1University	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	6	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	2	7	Hull	Hull	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	8	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	9	Cancer	Cancer	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	10	Biology	Biology	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	11	Proteomics	Proteomics	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	12	Group	Group	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	13	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	14	Hull	Hull	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	15	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	16	United	United	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	17	Kingdom	Kingdom	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	18	2University	2University	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	19	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	2	20	Hull	Hull	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	21	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	22	School	School	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	23	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	2	24	Biological	Biological	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	25	Biomedical	Biomedical	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	26	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	2	27	Environmental	Environmental	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	28	Sciences	Sciences	NNPS
work_newopgrnrzfqbeyqnf4pqkzeka	2	29	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	30	Hull	Hull	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	31	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	32	United	United	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	33	Kingdom	Kingdom	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	34	3Castle	3Castle	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	35	Hill	Hill	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	36	Hospital	Hospital	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	37	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	38	Academic	Academic	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	39	Surgical	Surgical	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	40	Unit	Unit	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	41	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	42	Hull	Hull	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	43	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	44	United	United	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	45	Kingdom	Kingdom	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	46	Purpose	Purpose	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	47	/	/	SYM
work_newopgrnrzfqbeyqnf4pqkzeka	2	48	Objective	Objective	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	2	49	:	:	:
work_newopgrnrzfqbeyqnf4pqkzeka	2	50	Despite	despite	IN
work_newopgrnrzfqbeyqnf4pqkzeka	2	51	significant	significant	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	2	52	research	research	NN
work_newopgrnrzfqbeyqnf4pqkzeka	2	53	input	input	NN
work_newopgrnrzfqbeyqnf4pqkzeka	2	54	aiming	aim	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	2	55	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	2	56	improve	improve	VB
work_newopgrnrzfqbeyqnf4pqkzeka	2	57	therapy	therapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	2	58	regimens	regimen	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	2	59	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	2	60	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	2	61	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	2	62	remains	remain	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	2	63	as	as	IN
work_newopgrnrzfqbeyqnf4pqkzeka	2	64	one	one	CD
work_newopgrnrzfqbeyqnf4pqkzeka	2	65	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	2	66	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	2	67	cancers	cancer	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	2	68	with	with	IN
work_newopgrnrzfqbeyqnf4pqkzeka	2	69	significant	significant	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	2	70	morbidity	morbidity	NN
work_newopgrnrzfqbeyqnf4pqkzeka	2	71	rates	rate	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	2	72	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	3	1	Radiotherapy	radiotherapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	3	2	has	have	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	3	3	been	be	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	3	4	shown	show	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	3	5	to	to	IN
work_newopgrnrzfqbeyqnf4pqkzeka	3	6	lower	lower	VB
work_newopgrnrzfqbeyqnf4pqkzeka	3	7	10-year	10-year	CD
work_newopgrnrzfqbeyqnf4pqkzeka	3	8	local	local	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	3	9	recurrence	recurrence	NN
work_newopgrnrzfqbeyqnf4pqkzeka	3	10	by	by	IN
work_newopgrnrzfqbeyqnf4pqkzeka	3	11	approximately	approximately	RB
work_newopgrnrzfqbeyqnf4pqkzeka	3	12	50	50	CD
work_newopgrnrzfqbeyqnf4pqkzeka	3	13	%	%	NN
work_newopgrnrzfqbeyqnf4pqkzeka	3	14	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	4	1	A	a	DT
work_newopgrnrzfqbeyqnf4pqkzeka	4	2	substantial	substantial	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	4	3	number	number	NN
work_newopgrnrzfqbeyqnf4pqkzeka	4	4	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	4	5	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	4	6	tumours	tumour	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	4	7	fail	fail	VBP
work_newopgrnrzfqbeyqnf4pqkzeka	4	8	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	4	9	respond	respond	VB
work_newopgrnrzfqbeyqnf4pqkzeka	4	10	to	to	IN
work_newopgrnrzfqbeyqnf4pqkzeka	4	11	radiotherapy	radiotherapy	VB
work_newopgrnrzfqbeyqnf4pqkzeka	4	12	which	which	WDT
work_newopgrnrzfqbeyqnf4pqkzeka	4	13	not	not	RB
work_newopgrnrzfqbeyqnf4pqkzeka	4	14	only	only	RB
work_newopgrnrzfqbeyqnf4pqkzeka	4	15	presents	present	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	4	16	a	a	DT
work_newopgrnrzfqbeyqnf4pqkzeka	4	17	barrier	barrier	NN
work_newopgrnrzfqbeyqnf4pqkzeka	4	18	for	for	IN
work_newopgrnrzfqbeyqnf4pqkzeka	4	19	effective	effective	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	4	20	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	4	21	treatment	treatment	NN
work_newopgrnrzfqbeyqnf4pqkzeka	4	22	bu	bu	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	4	23	also	also	RB
work_newopgrnrzfqbeyqnf4pqkzeka	4	24	means	mean	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	4	25	that	that	IN
work_newopgrnrzfqbeyqnf4pqkzeka	4	26	those	those	DT
work_newopgrnrzfqbeyqnf4pqkzeka	4	27	patients	patient	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	4	28	with	with	IN
work_newopgrnrzfqbeyqnf4pqkzeka	4	29	therapy	therapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	4	30	resistant	resistant	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	4	31	tumours	tumour	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	4	32	endure	endure	VBP
work_newopgrnrzfqbeyqnf4pqkzeka	4	33	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	4	34	harmful	harmful	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	4	35	side	side	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	4	36	effects	effect	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	4	37	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	4	38	radiotherapy	radiotherapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	4	39	for	for	IN
work_newopgrnrzfqbeyqnf4pqkzeka	4	40	no	no	DT
work_newopgrnrzfqbeyqnf4pqkzeka	4	41	therapeutic	therapeutic	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	4	42	gain	gain	NN
work_newopgrnrzfqbeyqnf4pqkzeka	4	43	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	5	1	Therefore	therefore	RB
work_newopgrnrzfqbeyqnf4pqkzeka	5	2	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	5	3	it	-PRON-	PRP
work_newopgrnrzfqbeyqnf4pqkzeka	5	4	is	be	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	5	5	important	important	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	5	6	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	5	7	identify	identify	VB
work_newopgrnrzfqbeyqnf4pqkzeka	5	8	biomarkers	biomarker	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	5	9	capable	capable	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	5	10	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	5	11	predicting	predict	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	5	12	a	a	DT
work_newopgrnrzfqbeyqnf4pqkzeka	5	13	tumour	tumour	NN
work_newopgrnrzfqbeyqnf4pqkzeka	5	14	's	's	POS
work_newopgrnrzfqbeyqnf4pqkzeka	5	15	response	response	NN
work_newopgrnrzfqbeyqnf4pqkzeka	5	16	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	5	17	radiotherapy	radiotherapy	VB
work_newopgrnrzfqbeyqnf4pqkzeka	5	18	prior	prior	RB
work_newopgrnrzfqbeyqnf4pqkzeka	5	19	to	to	IN
work_newopgrnrzfqbeyqnf4pqkzeka	5	20	treatment	treatment	NN
work_newopgrnrzfqbeyqnf4pqkzeka	5	21	which	which	WDT
work_newopgrnrzfqbeyqnf4pqkzeka	5	22	can	can	MD
work_newopgrnrzfqbeyqnf4pqkzeka	5	23	improve	improve	VB
work_newopgrnrzfqbeyqnf4pqkzeka	5	24	therapy	therapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	5	25	outcomes	outcome	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	5	26	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	6	1	The	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	6	2	aim	aim	NN
work_newopgrnrzfqbeyqnf4pqkzeka	6	3	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	6	4	this	this	DT
work_newopgrnrzfqbeyqnf4pqkzeka	6	5	study	study	NN
work_newopgrnrzfqbeyqnf4pqkzeka	6	6	is	be	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	6	7	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	6	8	identify	identify	VB
work_newopgrnrzfqbeyqnf4pqkzeka	6	9	putative	putative	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	6	10	protein	protein	NN
work_newopgrnrzfqbeyqnf4pqkzeka	6	11	biomarkers	biomarker	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	6	12	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	6	13	radiotherapy	radiotherapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	6	14	resistance	resistance	NN
work_newopgrnrzfqbeyqnf4pqkzeka	6	15	using	use	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	6	16	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	6	17	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	6	18	tissue	tissue	NN
work_newopgrnrzfqbeyqnf4pqkzeka	6	19	biopsy	biopsy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	6	20	samples	sample	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	6	21	by	by	IN
work_newopgrnrzfqbeyqnf4pqkzeka	6	22	employing	employ	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	6	23	comparative	comparative	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	6	24	proteomic	proteomic	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	6	25	tools	tool	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	6	26	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	7	1	Ultimate	ultimate	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	7	2	aim	aim	NN
work_newopgrnrzfqbeyqnf4pqkzeka	7	3	is	be	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	7	4	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	7	5	translate	translate	VB
work_newopgrnrzfqbeyqnf4pqkzeka	7	6	these	these	DT
work_newopgrnrzfqbeyqnf4pqkzeka	7	7	biomarkers	biomarker	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	7	8	into	into	IN
work_newopgrnrzfqbeyqnf4pqkzeka	7	9	an	an	DT
work_newopgrnrzfqbeyqnf4pqkzeka	7	10	assay	assay	NN
work_newopgrnrzfqbeyqnf4pqkzeka	7	11	panel	panel	NN
work_newopgrnrzfqbeyqnf4pqkzeka	7	12	for	for	IN
work_newopgrnrzfqbeyqnf4pqkzeka	7	13	routine	routine	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	7	14	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	7	15	screening	screening	NN
work_newopgrnrzfqbeyqnf4pqkzeka	7	16	aiding	aid	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	7	17	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	7	18	personalisation	personalisation	NN
work_newopgrnrzfqbeyqnf4pqkzeka	7	19	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	7	20	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	7	21	treatment	treatment	NN
work_newopgrnrzfqbeyqnf4pqkzeka	7	22	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	8	1	Materials	material	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	8	2	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	8	3	Methods	method	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	8	4	:	:	:
work_newopgrnrzfqbeyqnf4pqkzeka	8	5	Following	follow	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	8	6	ethical	ethical	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	8	7	approval	approval	NN
work_newopgrnrzfqbeyqnf4pqkzeka	8	8	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	8	9	Sheffield	Sheffield	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	8	10	REC	REC	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	8	11	ref	ref	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	8	12	10	10	CD
work_newopgrnrzfqbeyqnf4pqkzeka	8	13	/	/	SYM
work_newopgrnrzfqbeyqnf4pqkzeka	8	14	H1308/37	H1308/37	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	8	15	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	8	16	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	8	17	two	two	CD
work_newopgrnrzfqbeyqnf4pqkzeka	8	18	pairs	pair	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	8	19	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	8	20	pre	pre	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	8	21	-	-	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	8	22	treatment	treatment	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	8	23	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	8	24	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	8	25	biopsy	biopsy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	8	26	samples	sample	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	8	27	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	8	28	radioresistant	radioresistant	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	8	29	versus	versus	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	8	30	radiosensitive	radiosensitive	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	8	31	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	8	32	were	be	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	8	33	investigated	investigate	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	8	34	using	use	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	8	35	antibody	antibody	NN
work_newopgrnrzfqbeyqnf4pqkzeka	8	36	microarray	microarray	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	8	37	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	8	38	identify	identify	VB
work_newopgrnrzfqbeyqnf4pqkzeka	8	39	differentially	differentially	RB
work_newopgrnrzfqbeyqnf4pqkzeka	8	40	expressed	express	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	8	41	proteins	protein	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	8	42	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	8	43	DEPs	DEPs	NNPS
work_newopgrnrzfqbeyqnf4pqkzeka	8	44	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	8	45	involved	involve	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	8	46	in	in	IN
work_newopgrnrzfqbeyqnf4pqkzeka	8	47	mediating	mediate	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	8	48	radiotherapy	radiotherapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	8	49	resistance	resistance	NN
work_newopgrnrzfqbeyqnf4pqkzeka	8	50	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	9	1	Data	datum	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	9	2	obtained	obtain	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	9	3	from	from	IN
work_newopgrnrzfqbeyqnf4pqkzeka	9	4	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	9	5	experiments	experiment	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	9	6	were	be	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	9	7	subjected	subject	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	9	8	to	to	IN
work_newopgrnrzfqbeyqnf4pqkzeka	9	9	data	datum	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	9	10	mining	mining	NN
work_newopgrnrzfqbeyqnf4pqkzeka	9	11	using	use	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	9	12	Ingenuity	Ingenuity	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	9	13	Pathway	Pathway	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	9	14	Analysis	Analysis	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	9	15	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	9	16	IPA	IPA	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	9	17	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	9	18	which	which	WDT
work_newopgrnrzfqbeyqnf4pqkzeka	9	19	mapped	map	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	9	20	these	these	DT
work_newopgrnrzfqbeyqnf4pqkzeka	9	21	DEPs	dep	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	9	22	onto	onto	IN
work_newopgrnrzfqbeyqnf4pqkzeka	9	23	their	-PRON-	PRP$
work_newopgrnrzfqbeyqnf4pqkzeka	9	24	most	most	RBS
work_newopgrnrzfqbeyqnf4pqkzeka	9	25	relevant	relevant	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	9	26	canonical	canonical	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	9	27	signalling	signal	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	9	28	pathways	pathway	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	9	29	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	10	1	Results	result	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	10	2	:	:	:
work_newopgrnrzfqbeyqnf4pqkzeka	10	3	The	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	10	4	antibody	antibody	NN
work_newopgrnrzfqbeyqnf4pqkzeka	10	5	microarray	microarray	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	10	6	analysis	analysis	NN
work_newopgrnrzfqbeyqnf4pqkzeka	10	7	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	10	8	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	10	9	clinical	clinical	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	10	10	samples	sample	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	10	11	revealed	reveal	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	10	12	25	25	CD
work_newopgrnrzfqbeyqnf4pqkzeka	10	13	DEPs	dep	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	10	14	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	10	15	46	46	CD
work_newopgrnrzfqbeyqnf4pqkzeka	10	16	DEPs	dep	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	10	17	from	from	IN
work_newopgrnrzfqbeyqnf4pqkzeka	10	18	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	10	19	first	first	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	10	20	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	10	21	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	10	22	second	second	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	10	23	experiment	experiment	NN
work_newopgrnrzfqbeyqnf4pqkzeka	10	24	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	10	25	respectively	respectively	RB
work_newopgrnrzfqbeyqnf4pqkzeka	10	26	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	11	1	The	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	11	2	IPA	ipa	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	11	3	analysis	analysis	NN
work_newopgrnrzfqbeyqnf4pqkzeka	11	4	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	11	5	these	these	DT
work_newopgrnrzfqbeyqnf4pqkzeka	11	6	combined	combine	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	11	7	generated	generate	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	11	8	253	253	CD
work_newopgrnrzfqbeyqnf4pqkzeka	11	9	canonical	canonical	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	11	10	pathways	pathway	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	11	11	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	12	1	Amongst	amongst	IN
work_newopgrnrzfqbeyqnf4pqkzeka	12	2	these	these	DT
work_newopgrnrzfqbeyqnf4pqkzeka	12	3	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	12	4	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	12	5	most	most	RBS
work_newopgrnrzfqbeyqnf4pqkzeka	12	6	interesting	interesting	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	12	7	pathways	pathway	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	12	8	included	include	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	12	9	p53	p53	NN
work_newopgrnrzfqbeyqnf4pqkzeka	12	10	signalling	signalling	NN
work_newopgrnrzfqbeyqnf4pqkzeka	12	11	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	12	12	12	12	CD
work_newopgrnrzfqbeyqnf4pqkzeka	12	13	DEPs	dep	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	12	14	mapped	map	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	12	15	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	12	16	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	12	17	death	death	NN
work_newopgrnrzfqbeyqnf4pqkzeka	12	18	receptor	receptor	NN
work_newopgrnrzfqbeyqnf4pqkzeka	12	19	signalling	signal	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	12	20	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	12	21	7	7	CD
work_newopgrnrzfqbeyqnf4pqkzeka	12	22	DEPs	DEPs	NNPS
work_newopgrnrzfqbeyqnf4pqkzeka	12	23	mapped	map	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	12	24	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	12	25	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	12	26	apoptosis	apoptosis	NN
work_newopgrnrzfqbeyqnf4pqkzeka	12	27	signalling	signalling	NN
work_newopgrnrzfqbeyqnf4pqkzeka	12	28	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	12	29	5	5	CD
work_newopgrnrzfqbeyqnf4pqkzeka	12	30	DEPs	dep	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	12	31	mapped	map	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	12	32	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	12	33	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	12	34	EGF	EGF	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	12	35	signalling	signal	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	12	36	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	12	37	4	4	CD
work_newopgrnrzfqbeyqnf4pqkzeka	12	38	DEPs	DEPs	NNPS
work_newopgrnrzfqbeyqnf4pqkzeka	12	39	mapped	map	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	12	40	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	12	41	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	13	1	Radiotherapy	radiotherapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	13	2	is	be	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	13	3	known	know	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	13	4	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	13	5	initiate	initiate	VB
work_newopgrnrzfqbeyqnf4pqkzeka	13	6	cellular	cellular	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	13	7	apoptosis	apoptosis	NN
work_newopgrnrzfqbeyqnf4pqkzeka	13	8	via	via	IN
work_newopgrnrzfqbeyqnf4pqkzeka	13	9	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	13	10	intrinsic	intrinsic	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	13	11	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	13	12	mitochondrial	mitochondrial	NN
work_newopgrnrzfqbeyqnf4pqkzeka	13	13	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	13	14	apoptotic	apoptotic	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	13	15	pathway	pathway	NN
work_newopgrnrzfqbeyqnf4pqkzeka	13	16	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	14	1	However	however	RB
work_newopgrnrzfqbeyqnf4pqkzeka	14	2	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	14	3	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	14	4	identification	identification	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	5	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	14	6	some	some	DT
work_newopgrnrzfqbeyqnf4pqkzeka	14	7	regulatory	regulatory	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	14	8	proteins	protein	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	14	9	involved	involve	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	14	10	in	in	IN
work_newopgrnrzfqbeyqnf4pqkzeka	14	11	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	14	12	extrinsic	extrinsic	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	13	pathway	pathway	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	14	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	14	15	death	death	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	16	receptor	receptor	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	17	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	14	18	apoptotic	apoptotic	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	14	19	pathway	pathway	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	20	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	14	21	Figure	figure	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	22	1	1	CD
work_newopgrnrzfqbeyqnf4pqkzeka	14	23	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	14	24	has	have	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	14	25	revealed	reveal	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	14	26	a	a	DT
work_newopgrnrzfqbeyqnf4pqkzeka	14	27	potential	potential	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	14	28	link	link	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	29	between	between	IN
work_newopgrnrzfqbeyqnf4pqkzeka	14	30	radiotherapy	radiotherapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	31	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	14	32	this	this	DT
work_newopgrnrzfqbeyqnf4pqkzeka	14	33	pathway	pathway	NN
work_newopgrnrzfqbeyqnf4pqkzeka	14	34	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	15	1	Figure	figure	NN
work_newopgrnrzfqbeyqnf4pqkzeka	15	2	1	1	CD
work_newopgrnrzfqbeyqnf4pqkzeka	15	3	:	:	:
work_newopgrnrzfqbeyqnf4pqkzeka	15	4	Death	death	NN
work_newopgrnrzfqbeyqnf4pqkzeka	15	5	Receptor	receptor	NN
work_newopgrnrzfqbeyqnf4pqkzeka	15	6	Signalling	signal	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	15	7	A	a	DT
work_newopgrnrzfqbeyqnf4pqkzeka	15	8	total	total	NN
work_newopgrnrzfqbeyqnf4pqkzeka	15	9	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	15	10	7	7	CD
work_newopgrnrzfqbeyqnf4pqkzeka	15	11	DEPs	DEPs	NNPS
work_newopgrnrzfqbeyqnf4pqkzeka	15	12	were	be	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	15	13	mapped	map	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	15	14	onto	onto	IN
work_newopgrnrzfqbeyqnf4pqkzeka	15	15	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	15	16	Death	Death	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	15	17	Receptor	Receptor	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	15	18	Signalling	Signalling	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	15	19	pathway	pathway	NN
work_newopgrnrzfqbeyqnf4pqkzeka	15	20	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	15	21	namely	namely	RB
work_newopgrnrzfqbeyqnf4pqkzeka	15	22	CRADD	cradd	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	15	23	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	15	24	TNFRSF25	TNFRSF25	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	15	25	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	15	26	MAPK8	mapk8	NN
work_newopgrnrzfqbeyqnf4pqkzeka	15	27	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	15	28	TNFSF10	TNFSF10	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	15	29	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	15	30	NFKB1	nfkb1	NN
work_newopgrnrzfqbeyqnf4pqkzeka	15	31	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	15	32	TNFRSF10A	TNFRSF10A	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	15	33	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	15	34	TNF	TNF	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	15	35	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	16	1	Conclusions	conclusion	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	16	2	:	:	:
work_newopgrnrzfqbeyqnf4pqkzeka	16	3	Antibody	antibody	NN
work_newopgrnrzfqbeyqnf4pqkzeka	16	4	microarray	microarray	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	16	5	analysis	analysis	NN
work_newopgrnrzfqbeyqnf4pqkzeka	16	6	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	16	7	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	16	8	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	16	9	biopsy	biopsy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	16	10	samples	sample	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	16	11	has	have	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	16	12	enabled	enable	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	16	13	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	16	14	identification	identification	NN
work_newopgrnrzfqbeyqnf4pqkzeka	16	15	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	16	16	a	a	DT
work_newopgrnrzfqbeyqnf4pqkzeka	16	17	number	number	NN
work_newopgrnrzfqbeyqnf4pqkzeka	16	18	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	16	19	DEPs	dep	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	16	20	which	which	WDT
work_newopgrnrzfqbeyqnf4pqkzeka	16	21	may	may	MD
work_newopgrnrzfqbeyqnf4pqkzeka	16	22	be	be	VB
work_newopgrnrzfqbeyqnf4pqkzeka	16	23	involved	involve	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	16	24	in	in	IN
work_newopgrnrzfqbeyqnf4pqkzeka	16	25	mediating	mediate	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	16	26	response	response	NN
work_newopgrnrzfqbeyqnf4pqkzeka	16	27	to	to	IN
work_newopgrnrzfqbeyqnf4pqkzeka	16	28	radiotherapy	radiotherapy	NN
work_newopgrnrzfqbeyqnf4pqkzeka	16	29	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	17	1	However	however	RB
work_newopgrnrzfqbeyqnf4pqkzeka	17	2	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	17	3	further	further	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	17	4	confirmation	confirmation	NN
work_newopgrnrzfqbeyqnf4pqkzeka	17	5	with	with	IN
work_newopgrnrzfqbeyqnf4pqkzeka	17	6	western	western	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	17	7	blotting	blotting	NN
work_newopgrnrzfqbeyqnf4pqkzeka	17	8	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	17	9	validation	validation	NN
work_newopgrnrzfqbeyqnf4pqkzeka	17	10	with	with	IN
work_newopgrnrzfqbeyqnf4pqkzeka	17	11	immunohistochemistry	immunohistochemistry	NN
work_newopgrnrzfqbeyqnf4pqkzeka	17	12	are	be	VBP
work_newopgrnrzfqbeyqnf4pqkzeka	17	13	required	require	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	17	14	before	before	IN
work_newopgrnrzfqbeyqnf4pqkzeka	17	15	such	such	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	17	16	biomarkers	biomarker	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	17	17	can	can	MD
work_newopgrnrzfqbeyqnf4pqkzeka	17	18	be	be	VB
work_newopgrnrzfqbeyqnf4pqkzeka	17	19	introduced	introduce	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	17	20	into	into	IN
work_newopgrnrzfqbeyqnf4pqkzeka	17	21	routine	routine	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	17	22	clinical	clinical	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	17	23	management	management	NN
work_newopgrnrzfqbeyqnf4pqkzeka	17	24	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	17	25	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	17	26	patients	patient	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	17	27	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	18	1	EP-1200	EP-1200	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	18	2	Validation	validation	NN
work_newopgrnrzfqbeyqnf4pqkzeka	18	3	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	18	4	a	a	DT
work_newopgrnrzfqbeyqnf4pqkzeka	18	5	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	18	6	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	18	7	outcome	outcome	NN
work_newopgrnrzfqbeyqnf4pqkzeka	18	8	prediction	prediction	NN
work_newopgrnrzfqbeyqnf4pqkzeka	18	9	model	model	NN
work_newopgrnrzfqbeyqnf4pqkzeka	18	10	in	in	IN
work_newopgrnrzfqbeyqnf4pqkzeka	18	11	routine	routine	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	18	12	Chinese	chinese	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	18	13	patients	patient	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	18	14	L.	L.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	18	15	Shen1	shen1	CD
work_newopgrnrzfqbeyqnf4pqkzeka	18	16	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	18	17	J.	J.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	19	1	Van	Van	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	19	2	Soest2	Soest2	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	19	3	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	19	4	J.	J.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	19	5	Wang1	wang1	NN
work_newopgrnrzfqbeyqnf4pqkzeka	19	6	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	19	7	J.	J.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	19	8	Yu3	Yu3	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	19	9	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	19	10	W.	W.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	19	11	Hu1	hu1	NN
work_newopgrnrzfqbeyqnf4pqkzeka	19	12	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	19	13	Y.U.T.	Y.U.T.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	1	Gong3	Gong3	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	2	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	3	V.	V.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	4	Valentini4	Valentini4	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	5	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	6	Y.	Y.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	7	Xiao3	Xiao3	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	8	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	9	A.	A.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	10	Dekker2	Dekker2	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	11	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	12	Z.	Z.	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	13	Zhang1	Zhang1	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	14	1Shanghai	1Shanghai	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	15	Medical	Medical	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	16	College	College	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	17	Fudan	Fudan	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	18	University	University	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	19	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	20	Radiation	Radiation	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	21	Oncology	Oncology	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	22	Department	Department	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	23	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	24	Shanghai	Shanghai	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	25	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	26	China	China	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	27	2GROW	2GROW	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	28	School	School	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	29	for	for	IN
work_newopgrnrzfqbeyqnf4pqkzeka	20	30	Oncology	Oncology	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	31	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	20	32	Developmental	Developmental	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	33	Biology	Biology	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	34	Maastricht	Maastricht	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	35	University	University	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	36	Medical	Medical	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	37	Centre	Centre	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	38	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	39	Radiation	Radiation	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	40	Oncology	Oncology	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	41	Department	Department	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	42	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	43	Maastricht	Maastricht	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	44	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	45	The	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	20	46	Netherlands	Netherlands	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	47	3Jefferson	3Jefferson	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	48	Medical	Medical	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	49	College	College	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	50	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	20	51	Thomas	Thomas	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	52	Jefferson	Jefferson	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	53	University	University	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	54	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	55	Radiation	Radiation	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	56	Oncology	Oncology	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	57	Department	Department	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	58	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	59	Philadelphia	Philadelphia	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	60	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	61	USA	USA	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	62	4Università	4Università	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	63	Cattolica	Cattolica	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	64	del	del	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	65	Sacro	Sacro	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	66	Cuore	Cuore	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	67	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	68	Radiation	Radiation	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	69	Oncology	Oncology	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	70	Department	Department	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	71	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	72	Rome	Rome	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	73	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	74	Italy	Italy	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	75	Purpose	Purpose	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	76	/	/	SYM
work_newopgrnrzfqbeyqnf4pqkzeka	20	77	Objective	Objective	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	20	78	:	:	:
work_newopgrnrzfqbeyqnf4pqkzeka	20	79	The	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	20	80	risk	risk	NN
work_newopgrnrzfqbeyqnf4pqkzeka	20	81	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	20	82	local	local	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	20	83	recurrence	recurrence	NN
work_newopgrnrzfqbeyqnf4pqkzeka	20	84	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	85	metastases	metastasis	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	20	86	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	20	87	overall	overall	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	20	88	survival	survival	NN
work_newopgrnrzfqbeyqnf4pqkzeka	20	89	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	20	90	locally	locally	RB
work_newopgrnrzfqbeyqnf4pqkzeka	20	91	advanced	advanced	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	20	92	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	20	93	cancer	cancer	NN
work_newopgrnrzfqbeyqnf4pqkzeka	20	94	after	after	IN
work_newopgrnrzfqbeyqnf4pqkzeka	20	95	preoperative	preoperative	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	20	96	chemoradiation	chemoradiation	NN
work_newopgrnrzfqbeyqnf4pqkzeka	20	97	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	20	98	curative	curative	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	20	99	surgery	surgery	NN
work_newopgrnrzfqbeyqnf4pqkzeka	20	100	can	can	MD
work_newopgrnrzfqbeyqnf4pqkzeka	20	101	be	be	VB
work_newopgrnrzfqbeyqnf4pqkzeka	20	102	estimated	estimate	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	20	103	by	by	IN
work_newopgrnrzfqbeyqnf4pqkzeka	20	104	prediction	prediction	NN
work_newopgrnrzfqbeyqnf4pqkzeka	20	105	models	model	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	20	106	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	20	107	visualized	visualize	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	20	108	using	use	VBG
work_newopgrnrzfqbeyqnf4pqkzeka	20	109	nomograms	nomogram	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	20	110	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	20	111	which	which	WDT
work_newopgrnrzfqbeyqnf4pqkzeka	20	112	have	have	VBP
work_newopgrnrzfqbeyqnf4pqkzeka	20	113	been	be	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	20	114	trained	train	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	20	115	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	20	116	validated	validate	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	20	117	in	in	IN
work_newopgrnrzfqbeyqnf4pqkzeka	20	118	European	european	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	20	119	clinical	clinical	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	20	120	trial	trial	NN
work_newopgrnrzfqbeyqnf4pqkzeka	20	121	populations	population	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	20	122	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	21	1	This	this	DT
work_newopgrnrzfqbeyqnf4pqkzeka	21	2	study	study	NN
work_newopgrnrzfqbeyqnf4pqkzeka	21	3	aims	aim	VBZ
work_newopgrnrzfqbeyqnf4pqkzeka	21	4	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	21	5	validate	validate	VB
work_newopgrnrzfqbeyqnf4pqkzeka	21	6	these	these	DT
work_newopgrnrzfqbeyqnf4pqkzeka	21	7	prediction	prediction	NN
work_newopgrnrzfqbeyqnf4pqkzeka	21	8	models	model	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	21	9	in	in	IN
work_newopgrnrzfqbeyqnf4pqkzeka	21	10	a	a	DT
work_newopgrnrzfqbeyqnf4pqkzeka	21	11	routine	routine	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	21	12	clinical	clinical	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	21	13	Chinese	chinese	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	21	14	cohort	cohort	NN
work_newopgrnrzfqbeyqnf4pqkzeka	21	15	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	22	1	Materials	material	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	22	2	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	22	3	Methods	method	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	22	4	:	:	:
work_newopgrnrzfqbeyqnf4pqkzeka	22	5	From	from	IN
work_newopgrnrzfqbeyqnf4pqkzeka	22	6	2006	2006	CD
work_newopgrnrzfqbeyqnf4pqkzeka	22	7	to	to	IN
work_newopgrnrzfqbeyqnf4pqkzeka	22	8	2012	2012	CD
work_newopgrnrzfqbeyqnf4pqkzeka	22	9	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	22	10	clinical	clinical	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	22	11	data	datum	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	22	12	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	22	13	277	277	CD
work_newopgrnrzfqbeyqnf4pqkzeka	22	14	consecutive	consecutive	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	22	15	locally	locally	RB
work_newopgrnrzfqbeyqnf4pqkzeka	22	16	advanced	advanced	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	22	17	rectal	rectal	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	22	18	adenocarcinoma	adenocarcinoma	NN
work_newopgrnrzfqbeyqnf4pqkzeka	22	19	patients	patient	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	22	20	treated	treat	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	22	21	with	with	IN
work_newopgrnrzfqbeyqnf4pqkzeka	22	22	preoperative	preoperative	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	22	23	chemoradiation	chemoradiation	NN
work_newopgrnrzfqbeyqnf4pqkzeka	22	24	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	22	25	curative	curative	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	22	26	surgery	surgery	NN
work_newopgrnrzfqbeyqnf4pqkzeka	22	27	from	from	IN
work_newopgrnrzfqbeyqnf4pqkzeka	22	28	a	a	DT
work_newopgrnrzfqbeyqnf4pqkzeka	22	29	single	single	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	22	30	Chinese	Chinese	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	22	31	Cancer	Cancer	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	22	32	Center	Center	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	22	33	,	,	,
work_newopgrnrzfqbeyqnf4pqkzeka	22	34	were	be	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	22	35	retrospectively	retrospectively	RB
work_newopgrnrzfqbeyqnf4pqkzeka	22	36	collected	collect	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	22	37	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	22	38	used	use	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	22	39	for	for	IN
work_newopgrnrzfqbeyqnf4pqkzeka	22	40	external	external	JJ
work_newopgrnrzfqbeyqnf4pqkzeka	22	41	validation	validation	NN
work_newopgrnrzfqbeyqnf4pqkzeka	22	42	.	.	.
work_newopgrnrzfqbeyqnf4pqkzeka	23	1	Concordance	Concordance	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	23	2	index	index	NN
work_newopgrnrzfqbeyqnf4pqkzeka	23	3	(	(	-LRB-
work_newopgrnrzfqbeyqnf4pqkzeka	23	4	C	C	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	23	5	-	-	HYPH
work_newopgrnrzfqbeyqnf4pqkzeka	23	6	index	index	NNP
work_newopgrnrzfqbeyqnf4pqkzeka	23	7	)	)	-RRB-
work_newopgrnrzfqbeyqnf4pqkzeka	23	8	and	and	CC
work_newopgrnrzfqbeyqnf4pqkzeka	23	9	calibration	calibration	NN
work_newopgrnrzfqbeyqnf4pqkzeka	23	10	curves	curve	NNS
work_newopgrnrzfqbeyqnf4pqkzeka	23	11	were	be	VBD
work_newopgrnrzfqbeyqnf4pqkzeka	23	12	used	use	VBN
work_newopgrnrzfqbeyqnf4pqkzeka	23	13	to	to	TO
work_newopgrnrzfqbeyqnf4pqkzeka	23	14	assess	assess	VB
work_newopgrnrzfqbeyqnf4pqkzeka	23	15	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	23	16	performance	performance	NN
work_newopgrnrzfqbeyqnf4pqkzeka	23	17	of	of	IN
work_newopgrnrzfqbeyqnf4pqkzeka	23	18	the	the	DT
work_newopgrnrzfqbeyqnf4pqkzeka	23	19	previously	previously	RB
work_newopgrnrzfqbeyqnf4pqkzeka	23	20	developed	develop	VBN